In recent years, several randomized clinical trials have been conducted by adding novel targeted agents to R-CHOP (the so-called R-CHOP + X mode) in order to improve outcomes for patients with non-GCB or activated B-cell-like (ABC) subtype of DLBCL, such as bortezomib [4], lenalidomide [5], or ibrutinib [6]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.